Skip to main content

Table 1 Ovarian cancer patient demographics by ß-blocker use

From: Use of ß-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study

 

Nonusers

Current users

Previous users

Number (%)

6,166 (93.06)

373 (5.63)

87 (1.31)

Age at diagnosis, years

   

 Median age (IQR)

65 (56–75)

66 (56–74)

63 (55–73)

 20-40

213 (3.45)

13 (3.49)

1 (1.15)

 41-60

1,982 (32.14)

118 (31.64)

32 (36.78)

 61-80

3,188 (51.70)

197 (52.82)

42 (48.28)

 >80

783 (12.70)

45 (12.06)

12 (13.79)

Stageb

   

 Localized

1,848 (29.97)

128 (34.32)

28 (32.18)

 Regional

1,931 (31.32)

97 (26.01)

16 (18.39)

 Distant

1,920 (31.14)

111 (29.76)

33 (37.93)

 Unknown/missing

467 (7.57)

37 (9.92)

10 (11.49)

Comorbidity levelc

   

 Low

4,127 (66.93)

251 (67.29)

58 (66.67)

 Moderate

1,512 (24.52)

88 (23.59)

26 (29.89)

 High

527 (8.55)

34 (9.12)

3 (3.45)

Comorbidities

   

 Hypertension

681 (11.04)

45 (12.06)

12 (13.79)

 Obesity

71 (1.15)

2 (0.54)

0 (0.00)

 Atrial fibrillation/flutter

222 (3.60)

22 (5.90)

8 (9.20)

 Angina pectoris

257 (4.17)

9 (2.41)

0 (0.00)

 Myocardial infarction

160 (2.59)

10 (2.68)

2 (2.30)

 Congestive heart failure

183 (2.97)

12 (3.22)

4 (4.60)

 Esophageal varices

5 (0.08)

1 (0.27)

0 (0.00)

 Tremor

4 (0.06)

0 (0.00)

0 (0.00)

 Anxiety

41 (0.66)

1 (0.27)

1 (1.15)

 Thyrotoxicosis

182 (2.95)

16 (4.29)

5 (5.75)

 COPD

227 (3.68)

13 (3.49)

4 (4.60)

 Migraines

78 (1.27)

3 (0.80)

2 (2.30)

 Stroke

223 (3.62)

21 (5.63)

4 (4.60)

 Chronic kidney disease

81 (1.31)

5 (1.34)

3 (3.45)

 Hysterectomy

358 (5.81)

24 (6.43)

7 (8.05)

 Tubal sterilization

204 (3.31)

11 (2.95)

3 (3.45)

Comedication use

   

 ACE-inhibitors

351 (5.69)

104 (27.88)

30 (34.48)

 ARBs

198 (3.21)

60 (16.09)

16 (18.39)

 Calcium channel blockers

407 (6.60)

112 (30.03)

31 (35.63)

 Diuretics

1,276 (20.69)

234 (62.73)

67 (77.01)

 Non-aspirin NSAIDs

1,852 (30.04)

220 (58.98)

51 (58.62)

 Aspirin

525 (8.51)

157 (42.09)

40 (45.98)

 Statins

320 (5.19)

111 (29.76)

28 (32.18)

 HRT

1,165 (18.89)

126 (33.78)

33 (37.93)

 Antipsychotics

336 (5.45)

41 (10.99)

8 (9.20)

 Anxiolytics

285 (4.62)

22 (5.90)

7 (8.05)

 Antidepressants

816 (13.23)

100 (26.81)

24 (27.59)

  1. ACE: angiotensin-converting enzyme; ARBs: angiotensin receptor blockers; NSAIDs: nonsteroidal anti-inflammatory drugs.
  2. a Defined as time between first and last prescription plus 90 days (assumed to be the average length of prescription).
  3. b Classified according to Summary Staging classification with the TNM grouping translated as localized (TNM: T1–4, N0, M0), regional (TNM: T1–4, N1–3, M0), distant (TNM: T1–4, N1–3, M1), or unknown/missing.
  4. c Computed using the Charlson Comorbidity Index (CCI) score categorized into low (0), medium (1–2), or high (3+).